Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|July 7, 2020
Sorrel to Open a New Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.
Advertisement
Sorrel Medical, an Israel-based developer and manufacturer of wearable drug delivery devices, announced on July 7, 2020 that it is opening a new manufacturing facility with cleanroom facilities to further scale its wearable drug delivery devices.
According to a company press release, the new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices. With the new 80-m2 cleanroom, the company will be able to increase its production capacity to hundreds of thousands of units per year.
“As Sorrel continues to grow, this new facility will enable us to support global pharmaceutical and biotechnology partners to bring next-generation drug delivery solutions to patients," said Bentsi Algazi, vice president of Operations at Sorrel, in the press release. "These enhanced production scale-up capabilities will enable us to positively impact countless patients living with chronic and high burden conditions."
Source:
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement